PEP Buddy Impact on Breathing, Exercise, and Sleep Quality in COPD Patients - Trial NCT06290245
Access comprehensive clinical trial information for NCT06290245 through Pure Global AI's free database. This phase not specified trial is sponsored by Cairo University and is currently Recruiting. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cairo University
Timeline & Enrollment
N/A
Mar 01, 2024
Dec 01, 2024
Primary Outcome
dyspnea
Summary
Exercise intolerance and sleeping problems are among the most common symptoms experienced by
 patients with chronic obstructive pulmonary disease (COPD), which is associated with lung
 dynamic hyperinflation (DH). There was evidence that positive expiratory pressure (PEP),
 which less costly devices could offer, could reduce DH.
 
 A positive expiratory pressure device improved COPD-related symptoms in more than 70% of
 patients with COPD.
 
 PEP buddy is an adjunct to current COPD therapies, such as inhalers and pulmonary
 rehabilitation. It provides a tool for self-management and breathing re-training, reducing
 dyspnea and improving quality of life.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06290245
Device Trial